Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ESH AL 2018 | FLT3 inhibitors in the treatment of AML

Farhad Ravandi • 4 May 2018
ESH AL 2018
Acute Myeloid Leukemia Leukemia Azacitidine Crenolanib Gilteritinib Midostaurin Quizartinib Sorafenib

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

More from Farhad Ravandi

The efficacy and convenience of an all-oral regimen of decitabine and venetoclax in AML 2:03
The efficacy and convenience of an all-oral regimen of decitabine and venetoclax in AML
Farhad Ravandi • 11 Jun 2025
Treating older or unfit patients with AML: the current standard and future directions 4:07
Treating older or unfit patients with AML: the current standard and future directions
Farhad Ravandi • 11 Jun 2025
The addition of venetoclax to hyper-CVAD-nelarabine and pegylated asparagine in T-ALL 2:19
The addition of venetoclax to hyper-CVAD-nelarabine and pegylated asparagine in T-ALL
Farhad Ravandi • 7 Sep 2024
Novel targets, combinations & treatments in AML: use of OGM, TP53 treatment strategies & ADCs
Andrew Wei et al. • 1 Oct 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals